Tetsuji Terazawa

Tetsuji Terazawa

Auto-generated profile, based on publicly available information

Tetsuji Terazawa

Cancer Chemotherapy Center, Osaka Medical and Pharmaceutical University , Takatsuki-City, Japan

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2022 in JCO Precision Oncology
Verified
Journal Article
Open access
YNYoshiaki Nakamura
Yoshiaki Nakamura
WOWataru Okamoto
Wataru Okamoto
TDTadamichi Denda
Tadamichi Denda
TNTomohiro Nishina
Tomohiro Nishina
YKYoshito Komatsu
Yoshito Komatsu
TYTakayuki Yoshino
Takayuki Yoshino
PURPOSE: Circulating tumor DNA (ctDNA) genotyping may guide targeted therapy for patients with advanced GI cancers. However, no studies have validated ctDNA genotyping for microsatellite instability (MSI) assessment in comparison with a tissue-based standard.PATIENTS AND METHODS: The performance of plasma-based MSI assessment using Guardant360, a next-generation sequencing–based ctDNA assay, was compared with that of tissue-based MSI assessment using a validated polymerase chain reaction–based method in patients with advanced GI cancers enrolled in GOZILA study, a nationwide ctDNA profiling study. The primary end points were overall percent agreement, positive percent agreement (PPA), and negative percent agreement. The efficacy of immune checkpoint inhibitor therapy was also evaluated.RESULTS: In 658 patients with advanced GI cancers who underwent both plasma and tissue testing for MSI, the overall percent agreement, PPA, and negative percent agreement were 98.2% (95% CI, 96.8 to 99.1), 71.4% (95% CI, 47.8 to 88.7), and 99.1% (95% CI, 98.0 to 99.7), respectively. In patients whose plasma samples had a ctDNA fraction ≥ 1.0%, the PPA was 100.0% (15/15; 95% CI, 78.2 to 100.0). Three patients with MSI-high (MSI-H) tumors detected only by ctDNA genotyping achieved clinical benefits after receiving anti–programmed cell death 1 therapy with the progression-free survival ranging from 4.3 to 16.7 months. One patient with an aggressive cancer of an unknown primary site benefited from pembrolizumab after rapid detection of MSI-H by ctDNA genotyping.CONCLUSION: ctDNA genotyping was able to detect MSI with high concordance to validated tissue-based MSI testing, especially in patients with tumors that have sufficient ctDNA shedding. Furthermore, ctDNA genotyping enabled identification of patients with MSI-H tumors who benefited from immune checkpoint inhibitor treatment.

12 September 2020 in The Oncologist
Verified
Journal Article
Open access
PDF file
TTTetsuji Terazawa
Tetsuji Terazawa
TKTakeshi Kato
Takeshi Kato
MGMasahiro Goto
Masahiro Goto
KOKatsuya Ohta
Katsuya Ohta
SNShingo Noura
Shingo Noura
TSTaroh Satoh
Taroh Satoh
Lessons Learned Panitumumab monotherapy showed favorable efficacy and feasibility in the treatment of frail or elderly patients with RAS WT unresectable CRC. It is especially effective for left‐sided tumors; therefore, panitumumab as first‐line treatment could be an additional therapeutic option for frail elderly patients, particularly in those who are unsuitable for upfront oxaliplatin‐based or irinotecan‐based combination regimens. Background First‐line panitumumab monotherapy is expected to be well tolerated and improve survival in patients ineligible for intensive chemotherapy. However, its safety and efficacy in chemotherapy‐naïve frail or elderly patients with unresectable RAS wild‐type (WT) colorectal cancer (CRC) have not been studied. The aim of this phase II trial was to evaluate the efficacy and safety of panitumumab as first‐line treatment. Methods We conducted a multicenter phase II study on patients aged ≥76 years or ≥65 years considered unsuitable for intensive chemotherapy. Panitumumab 6 mg/kg of intravenous infusion was administered every 2 weeks. The primary endpoint was disease control rate (DCR). Secondary endpoints included progression‐free survival (PFS), overall survival (OS), response rate (RR), time to treatment failure (TTF), and incidence of grade 3 or 4 toxicities. Results Thirty‐six patients [median age: 81 (range, 67‐88) years] were enrolled between February 2017 and August 2018. Two patients were excluded from the analysis of efficacy: one due to lack of image examination at baseline and the other due to lack of a measurable lesion. Thirty‐three (91.6%) patients had a performance status (PS) of 0 or 1, whereas two (5.6%) patients and one (2.8%) patient had a PS of 2 and 3, respectively. Twenty‐eight patients (77.8%) had left‐sided CRC, whereas eight (22.2%) had right‐sided CRC. The RR was 50.0% (95% CI, 32.4‐67.6), including three patients (8.8%) who had complete responses. 26.5% had stable diseases, resulting in a DCR of 76.5% (90% confidence interval [CI], 61.5‐87.7). The RR of patients with left‐ and right‐sided tumors was 65.4% (95% CI, 44.3‐82.8) and 0.0% (95% CI, 0.0‐36.9), respectively. Major grade 3 or 4 nonhematologic toxicities were rash (n=6, 16.7%), hypomagnesemia (n=4, 11.1%), fatigue (n=3, 8.3%), paronychia (n=2, 5.6%), and hyponatremia (n=2, 5.6%). The only grade 3 hematologic toxicity was neutropenia (n=1, 2.8%). Conclusion Panitumumab monotherapy showed favorable efficacy and feasibility in frail or elderly patients with RAS WT unresectable CRC. Survival analysis including OS, PFS and TTF is currently in progress.

30 September 2019 in The Oncologist
Verified
Journal Article
Open access
PDF file
TTTetsuji Terazawa
Tetsuji Terazawa
JMJin Matsuyama
Jin Matsuyama
MGMasahiro Goto
Masahiro Goto
RKRyohei Kawabata
Ryohei Kawabata
SEShunji Endo
Shunji Endo
TSTaroh Satoh
Taroh Satoh
Lessons Learned. Perioperative capecitabine and oxaliplatin (CapeOx) therapy showed favorable efficacy with sufficient pathological response. Small sample size limited the statistical power of this result. Perioperative CapeOx therapy showed good feasibility. Further studies with larger sample size are required to validate this novel approach. Background. D2 gastrectomy followed by adjuvant S‐1 is the standard therapy for patients (pts) with stage III gastric cancer (GC) in Japan; however, the outcome is not satisfactory. We examined the efficacy of perioperative capecitabine and oxaliplatin (CapeOx) in pts with GC. Methods. The eligibility criteria included confirmed clinical T3(SS)/T4a(SE) N1‐3 M0 GC according to the Japanese Classification (JCGC; 3rd English Edition). Three cycles of neoadjuvant CapeOx (NAC; capecitabine, 2,000 mg/m2 for 14 days; oxaliplatin, 130 mg/m2 on day 1, every 3 weeks) were administered, followed by five cycles of adjuvant CapeOx (AC) after D2 gastrectomy. The primary endpoint was the pathological response rate (pRR) according to the JCGC (≥grade 1b). Results. Thirty‐seven pts were enrolled on CapeOx. An R0 resection rate of 78.4% (n = 29) and a pRR of 54.1% (n = 20, p = .058; 90% confidence interval [CI], 39.4–68.2) were demonstrated. Among 27 pts who initiated AC, 21 (63.6%) completed the treatment. Grade 3–4 toxicities during NAC included neutropenia (8%), thrombocytopenia (8%), and anorexia (8%) and during AC included neutropenia (37%), diarrhea (4%), and anorexia (4%). Conclusion. Perioperative CapeOx showed good feasibility and favorable efficacy with sufficient pathological response, although statistical significance at .058 did not reach the commonly accepted cutoff of .05. The data obtained using this novel approach warrant further investigations.

1 January 2020 in Gastroenterology Review
Verified
Journal Article
Open access
Yoshihiro InoueYoshihiro Inoue
Yoshihiro Inoue
KYKeisuke Yokohama
Keisuke Yokohama
HOHIdeko Ohama
HIdeko Ohama
YTYusuke Tsuchimoto
Yusuke Tsuchimoto
TTTetsuji Terazawa
Tetsuji Terazawa
KUKazuhisa Uchiyama
Kazuhisa Uchiyama
Introduction Laparoscopic hepatectomy (LH) is very difficult to perform in patients with cirrhosis because of the haemor- rhagic and fibrotic nature of the liver, although there are various advantages to laparoscopic surgery. Aim To investigate the surgical outcomes, and efficacy and safety...

23 February 2021 in In Vivo
Verified
Journal Article
Closed access
PDF file
HKHiroyuki Koadama
Hiroyuki Koadama
TTTetsuji Terazawa
Tetsuji Terazawa
YIYasunobu Ishizuka
Yasunobu Ishizuka
HYHiroki Yukami
Hiroki Yukami
MAMasahiko Aoki
Masahiko Aoki
KHKazuhide Higuchi
Kazuhide Higuchi
Background/Aim: Neoadjuvant chemotherapy without radiation (NAC) shows favorable outcomes for locally advanced rectal cancer (LARC), however, the optimal regimen has not been determined yet. This study aimed to compare the efficacy and safety of oxaliplatin, irinotecan, folinic acid, and 5-fluorouracil (mFOLFOXIRI) with capecitabine/S-1 and oxaliplatin (XELOX/SOX) in rectal cancer patients. Patients and Methods: We retrospectively examined patients with LARC who received mFOLFOXIRI or XELOX/SOX as NAC. Results: Between January 2015 and July 2019, 49 patients received mFOLFOXIRI and 37 patients received XELOX/SOX. The pathological response rates (over two-thirds affected tumor area) were 36.7% and 40.5% in the mFOLFOXIRI and XELOX/SOX groups, respectively. Grade 3/4 neutropenia was experienced by 45.0% of the patients in the mFOLFOXIRI group and 8.0% in the XEOX/SOX group. Conclusion: Although pathological responses were comparable between two groups, mFOLFOXIRI tended to be more toxic compared to XELOX/SOX as NAC for LARC.

13 December 2018 in Asia-Pacific Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
HYHiroki Yukami
Hiroki Yukami
TTTetsuji Terazawa
Tetsuji Terazawa
MGMasahiro Goto
Masahiro Goto
MAMasahiko Aoki
Masahiko Aoki
KAKen Asaishi
Ken Asaishi
KHKazuhide Higuchi
Kazuhide Higuchi